The estimated Net Worth of Elaine D Sun is at least $1.93 Million dollars as of 1 April 2021. Ms Sun owns over 10,196 units of Halozyme Therapeutics stock worth over $1,073,593 and over the last 5 years she sold HALO stock worth over $0. In addition, she makes $859,584 as Sr. VP & CFO at Halozyme Therapeutics.
Ms has made over 2 trades of the Halozyme Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 10,196 units of HALO stock worth $605,540 on 1 April 2021.
The largest trade she's ever made was exercising 12,166 units of Halozyme Therapeutics stock on 2 March 2021 worth over $722,539. On average, Ms trades about 2,485 units every 3 days since 2020. As of 1 April 2021 she still owns at least 18,077 units of Halozyme Therapeutics stock.
You can see the complete history of Ms Sun stock trades at the bottom of the page.
Elaine D. Sun is the Sr. VP & CFO at Halozyme Therapeutics.
As the Sr. VP & CFO of Halozyme Therapeutics, the total compensation of Ms Sun at Halozyme Therapeutics is $859,584. There are 2 executives at Halozyme Therapeutics getting paid more, with Helen Torley having the highest compensation of $5,857,130.
Ms Sun is 49, she's been the Sr. VP & CFO of Halozyme Therapeutics since . There are 10 older and no younger executives at Halozyme Therapeutics. The oldest executive at Halozyme Therapeutics Inc. is Connie Matsui, 66, who is the Independent Chairman of the Board.
Elaine's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 720, EMERYVILLE, CA, 94608.
Over the last 18 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay und Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
Halozyme Therapeutics executives and other stock owners filed with the SEC include: